Skip to main content
. 2017 Dec;363(3):419–427. doi: 10.1124/jpet.117.244152

Fig. 6.

Fig. 6.

ERK1/2 inhibition decreases KIM-1 mRNA and nuclear and cytosolic STAT3 phosphorylation under physiologic conditions in naive mice. (A) Representative immunoblot of nuclear phosphorylated STAT3 (S727 and Y705) and total STAT3 in naive mice after 4-hour treatment with trametinib. (B) KIM-1 mRNA measured at 4 hours post-treatment with trametinib. (C and D) Densitometry analysis of nuclear phosphorylated STAT3 (S727 and Y705) compared with total STAT3. (E) Representative immunoblot of cytosol phosphorylated STAT3 (S727 and Y705) and total STAT3 in naive mice after 4-hour treatment with trametinib. (F) Densitometry analysis of cytosol phosphorylated STAT3 (S727 and Y705) compared with total STAT3. (G) Densitometry analysis of nuclear and cytosol phosphorylated ERK1/2 compared with total ERK1/2. (H) Representative and verification renal immunoblot of nuclear and cytosol control proteins with and without trametinib treatment. Data are represented as mean ± S.E.M., n ≥ 6. Different superscripts indicate statistically significant differences (P < 0.05).